Candel Therapeutics Showcases Positive Clinical Trial Data for CAN-2409 in Cancer Immunotherapy

Reuters01-12

Candel <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Showcases Positive Clinical Trial Data for CAN-2409 in Cancer Immunotherapy

Candel Therapeutics Inc. has released a corporate presentation highlighting key developments in its oncology pipeline. The company reported positive results from a phase 3 randomized placebo-controlled clinical trial of its lead candidate, CAN-2409, in localized, intermediate- to high-risk prostate cancer. Positive overall survival data were also observed in randomized phase 2a clinical trials of CAN-2409 for borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer. The presentation notes ongoing precommercialization activities for CAN-2409 and outlines the company’s financial position, including $87.0 million in cash and cash equivalents as of September 30, 2025, and a term loan facility of up to $130 million. Additional upcoming clinical milestones in prostate cancer, non-small cell lung cancer, and recurrent high-grade glioma are detailed. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602560847?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 11:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602560847","market":"fut","top_or_hot":-1,"title":"Candel Therapeutics Showcases Positive Clinical Trial Data for CAN-2409 in Cancer Immunotherapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Candel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Showcases Positive Clinical Trial Data for CAN-2409 in Cancer Immunotherapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Candel Therapeutics Inc. has released a corporate presentation highlighting key developments in its oncology pipeline. The company reported positive results from a phase 3 randomized placebo-controlled clinical trial of its lead candidate, CAN-2409, in localized, intermediate- to high-risk prostate cancer. Positive overall survival data were also observed in randomized phase 2a clinical trials of CAN-2409 for borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer. The presentation notes ongoing precommercialization activities for CAN-2409 and outlines the company’s financial position, including $87.0 million in cash and cash equivalents as of September 30, 2025, and a term loan facility of up to $130 million. Additional upcoming clinical milestones in prostate cancer, non-small cell lung cancer, and recurrent high-grade glioma are detailed. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Candel Therapeutics Showcases Positive Clinical Trial Data for CAN-2409 in Cancer Immunotherapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCandel Therapeutics Showcases Positive Clinical Trial Data for CAN-2409 in Cancer Immunotherapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 11:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Candel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Showcases Positive Clinical Trial Data for CAN-2409 in Cancer Immunotherapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Candel Therapeutics Inc. has released a corporate presentation highlighting key developments in its oncology pipeline. The company reported positive results from a phase 3 randomized placebo-controlled clinical trial of its lead candidate, CAN-2409, in localized, intermediate- to high-risk prostate cancer. Positive overall survival data were also observed in randomized phase 2a clinical trials of CAN-2409 for borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer. The presentation notes ongoing precommercialization activities for CAN-2409 and outlines the company’s financial position, including $87.0 million in cash and cash equivalents as of September 30, 2025, and a term loan facility of up to $130 million. Additional upcoming clinical milestones in prostate cancer, non-small cell lung cancer, and recurrent high-grade glioma are detailed. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CADL","symbol_name":"Candel Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL1B0Kkg:1","article_id":"2602560847","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602560847","pubTimestamp":1768189995,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CADL":"Candel Therapeutics, Inc.","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Candel Therapeutics展示了CAN-2409在癌症免疫治疗中的积极临床试验数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CADL":0.9},"content_text":"Candel Therapeutics Showcases Positive Clinical Trial Data for CAN-2409 in Cancer Immunotherapy\n    \n\n        Candel Therapeutics Inc. has released a corporate presentation highlighting key developments in its oncology pipeline. The company reported positive results from a phase 3 randomized placebo-controlled clinical trial of its lead candidate, CAN-2409, in localized, intermediate- to high-risk prostate cancer. Positive overall survival data were also observed in randomized phase 2a clinical trials of CAN-2409 for borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer. The presentation notes ongoing precommercialization activities for CAN-2409 and outlines the company’s financial position, including $87.0 million in cash and cash equivalents as of September 30, 2025, and a term loan facility of up to $130 million. Additional upcoming clinical milestones in prostate cancer, non-small cell lung cancer, and recurrent high-grade glioma are detailed. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602560847","isCrawlerRequest":true}